Moving seasonal malaria chemoprevention out of its geographical isolation
-
Published:2023-10
Issue:10
Volume:23
Page:1102-1103
-
ISSN:1473-3099
-
Container-title:The Lancet Infectious Diseases
-
language:en
-
Short-container-title:The Lancet Infectious Diseases
Author:
Olotu Ally,Möhrle Jörg J
Subject
Infectious Diseases
Reference10 articles.
1. A novel multiple-stage antimalarial agent that inhibits protein synthesis;Baragaña;Nature,2015
2. Causal chemoprophylactic activity of cabamiquine against Plasmodium falciparum in a controlled human malaria infection: a randomised, double-blind, placebo-controlled study in the Netherlands;van der Plas;Lancet Infect Dis,2023
3. Inaugural meeting of the malaria policy advisory committee to the WHO: conclusions and recommendations;Malar J,2012
4. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study
5. Safety, tolerability, pharmacokinetics, and activity of the novel long-acting antimalarial DSM265: a two-part first-in-human phase 1a/1b randomised study;McCarthy;Lancet Infect Dis,2017